サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1338907

出血性疾患市場、シェア、規模、動向、産業分析レポート：タイプ別；薬剤クラス別；地域別；セグメント別予測、2023年～2032年

Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
出血性疾患市場、シェア、規模、動向、産業分析レポート：タイプ別；薬剤クラス別；地域別；セグメント別予測、2023年～2032年
出版日: 2023年06月23日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の出血性疾患市場規模は2032年までに274億9,000万米ドルに達する見込みです。同レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

血友病の最も一般的な種類は血友病Aであり、血液凝固第8因子が不十分な場合に発症します。米国疾病予防管理センター（CDC）によると、血友病Aは米国では10万人に10人の割合で発症しています。血液凝固第9因子が不足すると、血友病Bが発症します。CDCによると、血友病Bは米国人10万人におよそ3人が罹患しています。このことが、今後数年間の出血性疾患市場の成長と需要を牽引しています。

血友病Aの有病率の増加、同疾患に対する認識とスクリーニングの向上、新しい治療法の進歩、同疾患患者の平均余命の延長はすべて、出血性疾患市場の成長要因となっています。Statistaによると、血友病Aは2021年に世界で185,318人が罹患し、さらに17,951人がさまざまな血小板疾患に罹患しています。血友病AおよびBと診断される患者が増えるにつれて、凝固因子補充療法の需要が増加し、市場の成長を後押ししています。

血友病やvon Willebrand病などの出血性疾患は、血液中の凝固因子の欠乏や機能障害を特徴とします。出血性疾患の患者は、出血エピソードを予防または制御するために、凝固因子補充療法の定期的な注入を必要とします。これらの凝固因子は主に献血された血液や血漿に由来します。これらの凝固因子を産生するためには、ドナーの血液と血漿が入手できなければならないです。

出血性疾患の有病率が上昇しているため、献血や凝固因子補充療法の必要性が高まっています。世界保健機関（WHO）によると、2008年から2018年までに119カ国で1,070万件の自発的な無報酬献血の増加が記録されています。このことは、出血性疾患市場の成長に幅広い機会をもたらすと思われます。

HBVは年間60万～120万人の死亡者を出しており、感染患者の15～40％が致命的な肝疾患（肝硬変、肝不全、肝細胞がん）を発症しています。肝硬変や肝細胞がんの患者は、肝臓による凝固因子の産生が低下しているため、出血性疾患を発症するリスクが高いです。その結果、これらの患者では凝固因子補充療法の需要が高く、市場の成長を後押ししています。

出血性疾患市場レポートハイライト

血友病A型は、血友病Aの有病率の増加と新規治療に対する需要の高まりにより成長が予測されます。

遺伝子組換え凝固因子濃縮製剤は、予防需要の高まりと製造技術の進歩により、高い成長率を占める。

アジア太平洋地域は、出血性疾患の有病率の増加と研究開発への投資により、大きな成長率が見込まれています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の出血性疾患市場に関する洞察

  • 出血性疾患市場- 業界スナップショット
  • 出血性疾患の市場力学
    • 促進要因と機会
      • 血友病有病率の上昇
      • 新興諸国における出血疾患に対する意識の高まり
    • 抑制要因と課題
      • 出血性疾患の治療費は高額
  • PESTLE分析
  • 出血性疾患の業界動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の出血性疾患市場、種類別

  • 主な調査結果
  • イントロダクション
  • 血友病A
  • 血友病B
  • フォン・ヴィレブランド病

第6章 世界の出血性疾患市場、薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • 血漿由来凝固因子濃縮物
  • 組換え由来凝固因子
  • デスモプレシン
  • 抗線溶薬
  • フィブリンシーラント

第7章 世界の出血性疾患市場、地域別

  • 主な調査結果
  • イントロダクション
    • 出血性疾患市場評価、地域、2019-2032年
  • 出血性疾患市場-北米
    • 北米：出血性疾患市場、薬剤クラス別、2019～2032年
    • 北米：出血性疾患市場、種類別、2019～2032年
    • 出血性疾患市場-米国
    • 出血性疾患市場- カナダ
  • 出血性疾患市場- 欧州
    • 欧州：出血性疾患市場、薬剤クラス別、2019～2032年
    • 欧州：出血性疾患市場、種類別、2019～2032年
    • 出血性疾患市場- 英国
    • 出血性疾患市場- フランス
    • 出血性疾患市場- ドイツ
    • 出血性疾患市場- イタリア
    • 出血性疾患市場- スペイン
    • 出血性疾患市場- オランダ
    • 出血性疾患市場- ロシア
  • 出血性疾患市場- アジア太平洋
    • アジア太平洋：出血性疾患市場、薬剤クラス別、2019～2032年
    • アジア太平洋地域：出血性疾患市場、種類別、2019～2032年
    • 出血性疾患市場- 中国
    • 出血性疾患市場- インド
    • 出血性疾患市場- マレーシア
    • 出血性疾患市場- 日本
    • 出血性疾患市場- インドネシア
    • 出血性疾患市場- 韓国
  • 出血性疾患市場-中東およびアフリカ
    • 中東およびアフリカ：出血性疾患市場、薬剤クラス別、2019～2032年
    • 中東およびアフリカ：出血性疾患市場、種類別、2019～2032年
    • 出血性疾患市場- サウジアラビア
    • 出血性疾患市場- アラブ首長国連邦
    • 出血性疾患市場- イスラエル
    • 出血性疾患市場- 南アフリカ
  • 出血性疾患市場-ラテンアメリカ
    • ラテンアメリカ：出血性疾患市場、薬剤クラス別、2019～2032年
    • ラテンアメリカ：出血性疾患市場、種類別、2019～2032年
    • 出血性疾患市場- メキシコ
    • 出血性疾患市場- ブラジル
    • 出血性疾患市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Novo Nordisk
  • Bayer
  • Baxter
  • Alnylam Pharmaceuticals
  • Xenetic Biosciences
  • Bristol-Myers
  • Sanofi
  • Amgen
  • Janssen
  • Bioverativ Inc
図表

List of Tables

  • Table 1 Global Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 5 North America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 7 U.S.: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 Canada: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 11 Europe: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 12 UK: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 13 UK: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 14 France: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 France: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 17 Germany: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 19 Italy: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 Spain: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 25 Russia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 28 China: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 29 China: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 30 India: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 31 India: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 35 Japan: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 South Korea: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 UAE: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 47 Israel: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 49 South Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Latin America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 53 Mexico: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 55 Brazil: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 Argentina: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Bleeding Disorders Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Drug Class
  • Figure 7 Global Bleeding Disorders Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Type
  • Figure 9 Global Bleeding Disorders Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10 Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Bleeding Disorders Market
目次
Product Code: PM3351

The global bleeding disorders market size is expected to reach USD 27.49 billion by 2032, according to a new study by Polaris Market Research. The report "Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The most prevalent kind of hemophilia is hemophilia A. It occurs when there is insufficient clotting factor 8. According to the Centres for Disease Control and Prevention (CDC), hemophilia A affects roughly 10 in every 100,000 persons in the United States. When clotting factor 9 levels are insufficient, hemophilia B develops. According to the CDC, hemophilia B affects roughly 3 in 100,000 Americans. This is driving the growth and demand for the bleeding disorders market in coming years.

The increasing prevalence of hemophilia A, greater awareness and screening for the disease, advances in new therapies, and the longer life expectancy of patients with the disease are all contributing factors to the growth of the bleeding disorders market. According to Statista, Hemophilia A affected 185,318 persons globally in 2021, while another 17,951 people had various platelet diseases. As more patients are diagnosed with hemophilia A and B, the demand for clotting factor replacement therapy increases, which fuels the growth of the market.

Bleeding disorders, such as hemophilia and von Willebrand disease, are characterized by a deficiency or dysfunction of clotting factors in the blood. Patients with bleeding disorders require regular infusions of clotting factor replacement therapy to prevent or control bleeding episodes. These clotting factors are primarily derived from donated blood and plasma. In order to produce these clotting factors, donor blood and plasma must be available.

Due to the rising prevalence of bleeding diseases, there is an increase in need for blood donations as well as clotting factor replacement therapy. According to the World Health Organization, 119 nations have recorded an increase in voluntary unpaid blood donations of 10.7 million from 2008 to 2018. This will create a wide range of opportunities for the growth of the bleeding disorders market.

HBV causes 600,000 to 1.2 million fatalities annually, with 15-40% of infected patients developing fatal liver conditions (cirrhosis, liver failure, and hepatocellular carcinoma). Patients with liver cirrhosis and HCC are at an increased risk of developing bleeding disorders due to the decreased production of clotting factors by the liver. As a result, the demand for clotting factor replacement therapy is high among these patients, which fuels the growth of the market.

Bleeding Disorders Market Report Highlights

Hemophilia A Type is anticipated to grow due to the increasing prevalence of hemophilia A and rising demand for novel therapies.

Recombinant Coagulation Factor Concentrates segment accounted for the higher growth rate owing to the growing demand for prophylaxis and advancements in manufacturing technology.

Asia Pacific is expected to grow at a significant growth rate owing to the increasing prevalence of bleeding disorders and investments in research & development.

The global players include: Novo Nordisk, Bayer, Baxter International, Alnylam Pharmaceuticals, Pfizer, Xenetic Biosciences, Bristol, Sanofi, Amgen, Janssen, and Bioverativ Inc.

Polaris Market Research has segmented the bleeding disorders market report based on type, drug class and region:

Bleeding Disorders, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Diseases

Bleeding Disorders, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Plasma Derived Coagulation Factor Concentrates
  • Recombinant Derived Coagulation Factor
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants

Bleeding Disorders, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Bleeding Disorders Market Insights

  • 4.1. Bleeding Disorders Market - Industry Snapshot
  • 4.2. Bleeding Disorders Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in prevalence of hemophilia
      • 4.2.1.2. Rise in awareness about bleeding disorders in developing countries
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of bleeding disorders treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Bleeding Disorders Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Bleeding Disorders Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Bleeding Disorders, by Type, 2019-2032 (USD Billion)
  • 5.3. Hemophilia A
    • 5.3.1. Global Bleeding Disorders Market, by Hemophilia A, by Region, 2019-2032 (USD Billion)
  • 5.4. Hemophilia B
    • 5.4.1. Global Bleeding Disorders Market, by Hemophilia B, by Region, 2019-2032 (USD Billion)
  • 5.5. Von Willebrand Diseases
    • 5.5.1. Global Bleeding Disorders Market, by Von Willebrand Diseases, by Region, 2019-2032 (USD Billion)

6. Global Bleeding Disorders Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • 6.3. Plasma Derived Coagulation Factor Concentrates
    • 6.3.1. Global Bleeding Disorders Market, by Plasma Derived Coagulation Factor Concentrates, by Region, 2019-2032 (USD Billion)
  • 6.4. Recombinant Derived Coagulation Factor
    • 6.4.1. Global Bleeding Disorders Market, by Recombinant Derived Coagulation Factor, by Region, 2019-2032 (USD Billion)
  • 6.5. Desmopressin
    • 6.5.1. Global Bleeding Disorders Market, by Electric, by Region, 2019-2032 (USD Billion)
  • 6.6. Antifibrinolytics
    • 6.6.1. Global Bleeding Disorders Market, by Antifibrinolytics, by Region, 2019-2032 (USD Billion)
  • 6.7. Fibrin Sealants
    • 6.7.1. Global Bleeding Disorders Market, by Fibrin Sealants, by Region, 2019-2032 (USD Billion)

7. Global Bleeding Disorders Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Bleeding Disorders Market - North America
    • 7.3.1. North America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.3.2. North America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.3.3. Bleeding Disorders Market - U.S.
      • 7.3.3.1. U.S.: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.3.4. Bleeding Disorders Market - Canada
      • 7.3.4.1. Canada: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.4. Bleeding Disorders Market - Europe
    • 7.4.1. Europe: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.3. Bleeding Disorders Market - UK
      • 7.4.3.1. UK: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.4. Bleeding Disorders Market - France
      • 7.4.4.1. France: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.5. Bleeding Disorders Market - Germany
      • 7.4.5.1. Germany: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.6. Bleeding Disorders Market - Italy
      • 7.4.6.1. Italy: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.7. Bleeding Disorders Market - Spain
      • 7.4.7.1. Spain: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.8. Bleeding Disorders Market - Netherlands
      • 7.4.8.1. Netherlands: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.9. Bleeding Disorders Market - Russia
      • 7.4.9.1. Russia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.5. Bleeding Disorders Market - Asia Pacific
    • 7.5.1. Asia Pacific: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.3. Bleeding Disorders Market - China
      • 7.5.3.1. China: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.4. Bleeding Disorders Market - India
      • 7.5.4.1. India: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.5. Bleeding Disorders Market - Malaysia
      • 7.5.5.1. Malaysia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.6. Bleeding Disorders Market - Japan
      • 7.5.6.1. Japan: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.7. Bleeding Disorders Market - Indonesia
      • 7.5.7.1. Indonesia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.8. Bleeding Disorders Market - South Korea
      • 7.5.8.1. South Korea: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.6. Bleeding Disorders Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.3. Bleeding Disorders Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.4. Bleeding Disorders Market - UAE
      • 7.6.4.1. UAE: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.5. Bleeding Disorders Market - Israel
      • 7.6.5.1. Israel: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.6. Bleeding Disorders Market - South Africa
      • 7.6.6.1. South Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.7. Bleeding Disorders Market - Latin America
    • 7.7.1. Latin America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.3. Bleeding Disorders Market - Mexico
      • 7.7.3.1. Mexico: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.4. Bleeding Disorders Market - Brazil
      • 7.7.4.1. Brazil: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.5. Bleeding Disorders Market - Argentina
      • 7.7.5.1. Argentina: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Novo Nordisk
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bayer
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Baxter
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Alnylam Pharmaceuticals
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Xenetic Biosciences
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Bristol-Myers
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Sanofi
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Amgen
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Janssen
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Bioverativ Inc
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development